Full Press Release Details
Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain Manufacturer-to-Patient
Blockchain-enabled Tracking & Dispensing Platform for Prescription Drug Market
by DataVault AI's High-Performance Computing & Information Exchange, Data Monetization for Traditional and Compound Pharmacies
is Set to Become a Reality in the $639 Billion Prescription Drug Market, with Beta Testing Expected in First Half of 2026
FL, and PHILADELPHIA, PA October 27, 2025 - Wellgistics Health, Inc. ("Wellgistics") (NASDAQ: WGRX), a leader in
next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has
entered into a software as a service (SAAS) agreement with DataVault AI, Inc. ("DataVault") (NASDAQ: DVLT) , a pioneering
technology company leading the way in AI data experience, valuation, and monetization, to begin the development of manufacturer-to-patient
blockchain-enabled smart contracts ("PharmacyChain ") being designed to optimize Wellgistics' proprietary technology
and physical infrastructure for the prescription drug industry. The companies expect to finalize the related profit-sharing license agreement
in the fourth quarter of 2025, once all various potential revenue streams stemming from the partnership are identified and valued.
just the last few days, we have already received significant inbound interest from manufacturers, pharmacists and insurers who see the
significant benefit in being able to reliably close the loop on prescriptions reaching pharmacies, pharmacies rapidly qualifying them
for optimized insurance reimbursement and physicians receiving confirmation that patients actually receive their prescribed pharmaceutical
regimens," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics. "We are making the integration of smart
contracts a central pillar for our growth strategy going forward, allowing us to differentiate ourselves in the traditional pharmaceutical
distribution and compound pharmacy spaces. We expect PharmacyChain to allow us to gain market share in the markets we are already in,
as well as expand into new markets. Beta testing for PharmacyChain is expected to begin in the first half of 2026."
AI's Web 3.0 platform provides a proprietary IP and unique value proposition within the pharmaceutical distribution, pharmaceutical
manufacturer and compound pharmacy spaces. The patent protected technology, enabled by breakthrough smart contracts, will allow pharmacies
to securely and seamlessly receive and transfer data that will allow pharmacists to more easily make appropriate drug dispending decisions
for the benefit of patients and insurers.
that cover DataVault AI's blockchain and secure token driven data scoring, valuation, visualization and monetization on its patented
Information Data Exchange include, but are not limited to:
is also expected to allow manufacturers to better understand their key constituents, physicians and patients, in order to make more personalized
sales and marketing campaigns, as well as potentially expand upon the recent trend of direct-to-consumer cash sales. As part of Wellgistics'
desire to help improve patient outcomes, it also intends to ultimately include diagnostic and biometric data, on an opt-in basis, to
help further empower healthcare professionals and patients with data-driven recommendations based on gold-standard best practices from
leading physicians who leverage the power of biomarker and biometric data to help optimize health outcomes for their patients.
are excited to assist Wellgistics in developing new additive revenue streams within the $639 billion prescription drug market,"
said Nathaniel Bradley, President & CEO of DataVault AI. "Wellgistics has positioned themselves at the intersection of physical
and technology infrastructure in the pharmacy business. Our DataVault AI team will develop Digital Twins of pharmaceutical logistics,
delivery systems and patients. Utility tokens will ensure that every medicine you are prescribed will also be accompanied by recommendations
to optimize its use for your body by tailoring lifestyle and nutritional recommendations based upon your own personal health profile,
on a consented opt-in' basis. The objective is to align prescribed medicines with increasingly commonplace wellness regimens,
rooted in sound science and personal biomarker and biometric data obtained from the increasing use of wearable devices, which have demonstrated
improved outcomes in well controlled studies. Previously this was an overwhelming task, however with our technology we can make this
commonplace in healthcare's emerging high performance, data-driven era."
Wellgistics Health, Inc.
Health (NASDAQ: WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform
connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery,
and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic
alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.
more information, visit www.wellgisticshealth.com.
AI (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment.
The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data
Science Divisions. Datavault AI's Acoustic Science Division features WiSA , ADIO and Sumerian patented technologies and
industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization
and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing
to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides
comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues,
biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange (IDE) enables Digital Twins,
licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering
responsible AI with integrity. Datavault AI's technology suite is completely customizable and offers AI and Machine Learning (ML)
automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered
in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.
press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical
facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely
to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements
regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are
not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional
factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.
Health Media & Investor Contact
Health Investor Relations Contact
Corporate Communications Group, LLC
Avenue of the Americas, 5th Floor
Email: info@skylineccg.com
AI Corporate Communications